Bristol-Myers Squibb stock (US1078421011): Erste Group raises FY2026 EPS view

Erste Group Bank lifted its FY2026 EPS forecast for Bristol-Myers Squibb to $6.31 from $6.28 after strong Q1 results. Shares opened at $56.10 on Monday amid a Hold consensus rating.

Bristol-Myers Squibb released better-than-expected Q1 2026 results, with adjusted EPS of $1.58 beating the $1.42 consensus and revenue of $11.49 billion topping the $10.93 billion forecast, according to MarketBeat as of 05/11/2026. Following the earnings, Erste Group Bank analyst H. Engel raised the FY2026 EPS estimate to $6.31 per share from $6.28, slightly above the $6.30 consensus. The stock opened at $56.10 on the NYSE on May 11, 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bristol-Myers Squibb
• Sector/industry: Biopharmaceuticals
• Headquarters/country: United States
• Core markets: Oncology, immunology, cardiovascular
• Key revenue drivers: Eliquis, Opdivo, Orencia
• Home exchange/listing venue: NYSE (BMY)
• Trading currency: USD

Bristol-Myers Squibb: core business model

Bristol-Myers Squibb develops innovative medicines in oncology, hematology, immunology, cardiovascular and neuroscience therapeutic areas. The company focuses on blockbuster drugs like Eliquis for anticoagulation and Opdivo for cancer immunotherapy. With a strong pipeline of over 50 programs in clinical development as of late 2025 filings, it invests heavily in R&D, spending about 25% of revenue on innovation according to its latest annual report.

Main revenue and product drivers for Bristol-Myers Squibb

Key products drove Q1 2026 growth, with Eliquis generating significant sales alongside Opdivo and newer immunology assets. Revenue beat expectations amid stable demand in core markets, per the earnings release cited in MarketBeat as of 05/11/2026. The company maintains a diversified portfolio relevant to US investors through its dominant position in the $200+ billion US pharma market.

Industry trends and competitive position

In the biopharma sector, Bristol-Myers Squibb competes with Pfizer, Merck and Roche in oncology and immunology. Trends like immunotherapy expansion and biosimilar pressures shape its strategy, with recent pipeline advances bolstering its mid-cap status among US-listed peers. Its NYSE listing ensures liquidity for American retail investors tracking S&P 500 healthcare exposure.

Conclusion

Bristol-Myers Squibb's Q1 beat and Erste Group's raised FY2026 outlook highlight operational strength in a competitive biopharma landscape. With a Hold consensus and $61.31 average target, the stock reflects balanced analyst views amid pipeline progress. US investors monitor its NYSE performance for healthcare sector exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.